Hengzhun Biotechnology

Hengzhun Biotechnology is a specialized precision medicine company focused on the enrichment, detection, and analysis of circulating tumor cells (CTC) for cancer diagnostics. Founded in 2016 and headquartered in Shanghai, the company leverages its proprietary microfluidic chip technology and immuno-magnetic enrichment systems to provide high-sensitivity monitoring and early screening solutions for various solid tumors. Its flagship platform, Accu-CTC, enables non-invasive identification of CTCs in patients with lung, breast, and colorectal cancers, facilitating real-time treatment evaluation and prognosis monitoring. Hengzhun also operates a dedicated medical laboratory and collaborates with leading Chinese hospitals to integrate its liquid biopsy technologies into clinical practice. The company has successfully raised venture capital funding from prominent investors to advance its diagnostic pipeline and expand its commercial presence in the Chinese oncology market.